Revance Therapeutics (RVNC) Tops Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RVNC Hot Sheet
Join SI Premium – FREE
Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($0.71), $0.13 better than the analyst estimate of ($0.84). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $130 thousand.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arm Holdings (ARM) Tops Q2 EPS by 5c, Beats on Revenue; Offers Q3 Guidance
- Myriad Genetics to sell prenatal unit to Labcorp for $210M
- Corpay sells UK vehicle maintenance unit to OEConnection
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
